Guardant Health, Inc. (GH)财务
NASDAQ · Healthcare · Medical - Diagnostics & Research · 员工2,498人 · CEO Helmy Eltoukhy
- 股价
- $145.83 +0.16%
- 市值
- $197亿
- 企业价值
- $204亿 数据截至 2026-11-22
- 最近财报
- Q3 '26 2026-11-05提交
- 下次财报
- 2027-02-18 EPS预期 -$0.75
估值与关键数据
- 市值
- $197亿 2h 前更新
- 营收
- $12.8亿 过去12个月
- 营收增速
- +39% FY2026年一致预期
- 净利润率
- -37.9% 净利润 / 营收,TTM
- P/E
- 无市盈率 过去十二个月亏损
- P/S
- 15.4× 股价 / 营收,TTM
- EV / EBITDA
- -46.2× TTM
- 自由现金流
- -$2.32亿 过去12个月
- 净利润
- -$4.85亿 过去12个月
- 营收预期
- $13.7亿 FY2026年一致预期
- 盈利
- 2027-02-18 营收预估 $3.71亿 · 2h 前更新
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-11-05):营收超预期2.9%,EPS 超预期61.3%营收$3.61亿,预期$3.51亿(+2.9%);EPS -$0.29,预期-$0.75(+61.3%)。
- 营收增长放缓:同比36.1%Q3 '26营收$3.61亿,此前四个季度的平均值为42.6%。
- 营业利润率-39.4%(TTM),较去年同期+9.6 百分点营收增长41.7%,营业利润增长-13.9%。
- 资本支出占营收的4.6%(去年为4.4%)最近4个季度投入$5870万(同比+49.2%)。自由现金流-$2.32亿。
- 稀释股数一年内增加7.3%Q3 '26稀释股数1.34亿,一年前为1.25亿。
- 净债务 $6.65亿现金 + 短期投资 $10.3亿,含租赁债务 $16.9亿;一年前净债务 $7.46亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $3.61亿 | $2.65亿 | +36.1% |
| 毛利率 | 65.4% | 64.7% | +0.7 百分点 |
| 营业利润 | -$1.33亿 | -$9900万 | -34.1% |
| 营业利润率 | -36.8% | -37.3% | +0.5 百分点 |
| 净利润 | -$1.24亿 | -$9270万 | -34.1% |
| 稀释EPS | -$0.93 | -$0.74 | -25.7% |
| 经营现金流 | -$2370万 | -$3540万 | +33.1% |
| 资本支出 | $1350万 | $1040万 | +30.2% |
| 自由现金流 | -$3720万 | -$4580万 | +18.7% |
| R&D | $1.01亿 | $9000万 | +12.1% |
| 股权激励费用 | $6240万 | $4280万 | +45.8% |
实际 vs 一致预期
2026-11-05| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $3.61亿 | $3.51亿 | +2.9% |
| EPS(一致预期口径) | -$0.29 | -$0.75 | +61.3% |
来自2026-11-05发布的Q3 '26财报:营收及分析师预期口径的EPS(通常为调整后),可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占所列项目比例 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Oncology | $2.31亿 | +25.4% | 64.1% | $8.45亿 | – | |
| Screening | $6760万 | +180.4% | 18.7% | $1.97亿 | – | |
| Biopharma & Data | $5900万 | +7.7% | 16.3% | $2.27亿 | – | |
| Licensing & Other | $313万 | +60.2% | 0.9% | $951万 | – |
按地区划分的营收
占所列地区比例| 分部 | Q3 '26 | 同比 | 占所列项目比例 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $3.45亿 | +38.5% | 95.7% | $12.1亿 | +42.3% | |
| Non-US | $1560万 | -0.9% | 4.3% | $6730万 | +31.4% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$1.73亿
- 资本支出
- -$5870万
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $3.96亿
- 股权激励费用
- $2.11亿
- 自由现金流
- -$2.32亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | – | – | – |
| EV / EBITDA | -46.2× | – | – |
| EV / 营收 | 15.9× | 12.9× | 5.8× – 29.5× |
| 股价 / FCF | -85.0× | – | – |
| 股价 / 净资产 | -71.0× | 27.0× 5年中的3年 | 15.7× – 46.2× |
| FCF收益率 | -1.2% | -7.5% | -13.9% – -1.8% |
| 投入资本回报率 | -32.6% | -30.5% | -37.8% – -20.3% |
| 净资产收益率 | 249.0% | -144.2% | -1,087.7% – 419.2% |
分析师
一致目标价 $203.40 (+39.5%)
区间 $180.00 – $225.00 · 评级 Buy
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $13.7亿 | +39.2% | -$3.44 | -3.6% | -42.4× | 13 |
| FY2027 | $18.3亿 | +33.9% | -$2.27 | +34.0% | -64.2× | 13 |
| FY2028 | $25.1亿 | +36.9% | -$0.44 | +80.4% | -328.3× | 11 |
| FY2029 | $32亿 | +27.7% | $0.62 | +239.8% | 234.8× | 4 |
| FY2030 | $38.4亿 | +19.9% | $0.69 | +11.1% | 211.3× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Guardant Health, Inc.在近期10-Q / 10-K文件中标记的全部245项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| 应付账款 | $1.03亿 | $2010万 | +408.9% | $5440万 | $3860万 | +41.2% |
| 应收账款净额 | $1.87亿 | $1.16亿 | +61.4% | $1.38亿 | $1.1亿 | +25.0% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $0 | $0 | – | $588万 | $677万 | -13.2% |
| Accrued Employee Benefits, Current | $1.28亿 | $9820万 | +29.9% | $1.2亿 | $8320万 | +43.8% |
| 应计负债(流动) | $1.05亿 | $7170万 | +46.3% | $7790万 | $6830万 | +14.0% |
| 物业、厂房及设备累计折旧 | $2.24亿 | $1.91亿 | +17.2% | $1.99亿 | $1.66亿 | +20.2% |
| 累计其他综合收益(亏损) | -$513万 | -$426万 | -20.5% | -$485万 | -$520万 | +6.7% |
| Additional Paid in Capital | $30.8亿 | $25.6亿 | +20.3% | $29亿 | $24.4亿 | +18.7% |
| Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | – | – | – | $1770万 | – | – |
| Advertising Expense | – | – | – | $2410万 | $0 | – |
| Amortization of Debt Discount (Premium) | -$171万 | -$170万 | -0.8% | -$593万 | $0 | – |
| Amortization of Debt Issuance Costs | $118万 | $76.8万 | +54.0% | $324万 | $258万 | +25.6% |
| 无形资产摊销 | $30万 | $40万 | -25.0% | $170万 | $220万 | -22.7% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2680万 | 2720万 | -1.8% | 2610万 | 1920万 | +35.8% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $6240万 | $4280万 | +45.8% | $1.66亿 | $1.4亿 | +18.4% |
| Asset Impairment Charges | – | – | – | $0 | – | – |
| 总资产 | $18.9亿 | $12.8亿 | +47.7% | $20.1亿 | $14.9亿 | +35.5% |
| 流动资产 | $13.4亿 | $8.29亿 | +62.1% | $14.7亿 | $10.6亿 | +38.9% |
| Assets, Fair Value Disclosure | $12.6亿2025-12-31 | $9.04亿 | +39.0% | $12.6亿 | $9.04亿 | +39.0% |
| Business Combination, Contingent Consideration, Liability | $3400万 | – | – | $3400万 | $605万 | +462.0% |
| Capital Expenditures Incurred but Not yet Paid | – | – | – | $411万 | $381万 | +7.9% |
| 现金及现金等价物 | $10.3亿 | $5.8亿 | +77.0% | $3.78亿 | $5.26亿 | -28.0% |
| Cash and Cash Equivalents, Fair Value Disclosure | $10.3亿 | – | – | $4.34亿 | $5.9亿 | -26.4% |
| 现金、现金等价物及受限现金 | $11.5亿 | $6.9亿 | +66.2% | $4.89亿 | $6.3亿 | -22.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$2170万 | -$4600万 | +52.7% | -$1.4亿 | -$5.04亿 | +72.2% |
| Common Stock, Capital Shares Reserved for Future Issuance | 2890万 | 3000万 | -3.6% | 2820万 | 2710万 | +3.7% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| 法定普通股 | 3.5亿 | 3.5亿 | 0.0% | 3.5亿 | 3.5亿 | 0.0% |
| 已发行普通股 | 1.35亿 | 1.26亿 | +6.9% | 1.31亿 | 1.24亿 | +5.4% |
| 流通在外普通股 | 1.35亿 | 1.25亿 | +7.8% | 1.31亿 | 1.24亿 | +5.4% |
| Common Stock, Value, Outstanding | $1000 | $1000 | 0.0% | $1000 | $1000 | 0.0% |
| 综合收益(亏损) | -$1.24亿 | -$9330万 | -32.9% | -$4.16亿 | -$4.38亿 | +5.0% |
| Contract with Customer, Asset, after Allowance for Credit Loss | $640万 | $510万 | +25.5% | $520万 | $340万 | +52.9% |
| Contract with Customer, Liability | $4510万 | $5640万 | -20.0% | $5970万 | $4160万 | +43.5% |
| 合同负债(递延收入,流动) | $3810万 | $4690万 | -18.7% | $5080万 | $3550万 | +43.1% |
| Contract with Customer, Liability, Noncurrent | $700万 | $950万 | -26.3% | $900万 | $610万 | +47.5% |
| Contract with Customer, Liability, Revenue Recognized | $950万 | $920万 | +3.3% | $3530万2024-12-31 | $1450万 | +143.4% |
| Contract with Customer, Performance Obligation Satisfied in Previous Period | $840万 | $1680万 | -50.0% | $3380万 | $3530万 | -4.2% |
| Convertible Debt, Noncurrent | $15亿 | $11.1亿 | +34.8% | $15亿 | $11.4亿 | +31.6% |
| 销售成本 | $1.25亿 | $9360万 | +33.4% | $3.49亿 | $2.9亿 | +20.4% |
| Costs and Expenses | $4.94亿 | $3.64亿 | +35.6% | $14.2亿 | $11.8亿 | +20.0% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $35.2万 | $87.1万 | -59.6% |
| Current Income Tax Expense (Benefit) | – | – | – | $44.2万 | $99.7万 | -55.7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $9万 | $12.6万 | -28.6% |
| Debt Instrument, Face Amount | $10.9亿2025-09-30 | – | – | – | – | – |
| Debt Securities, Available-for-sale | $10.3亿 | – | – | $12.6亿 | $9.04亿 | +39.0% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $13万 | $23.2万 | -44.0% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $2.7万 | $4000 | +575.0% | $4万 | $0 | – |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease) | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $10.3亿 | – | – | $12.6亿 | $9.04亿 | +39.1% |
| Debt Securities, Available-for-sale, Current | $0 | $0 | – | $8.23亿 | $3.14亿 | +161.9% |
| Debt Securities, Current | $8.23亿2025-12-31 | $3.14亿 | +161.9% | $8.23亿 | $3.14亿 | +161.9% |
| Debt Securities, Realized Gain (Loss) | $0 | $0 | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$171万 | $28.7万 | -694.1% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$171万 | $28.7万 | -694.1% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $1820万2025-12-31 | $1440万 | +26.0% | $1820万 | $1440万 | +26.0% |
| Deferred Tax Assets, Gross | $8.4亿2025-12-31 | $7.34亿 | +14.4% | $8.4亿 | $7.34亿 | +14.4% |
| Deferred Tax Assets, in Process Research and Development | $1.34亿2025-12-31 | $1.18亿 | +13.6% | $1.34亿 | $1.18亿 | +13.6% |
| Deferred Tax Assets, Net of Valuation Allowance | $619万2025-12-31 | $76万 | +714.3% | $619万 | $76万 | +714.3% |
| Deferred Tax Assets, Operating Loss Carryforwards | $4.91亿2025-12-31 | $4.23亿 | +16.1% | $4.91亿 | $4.23亿 | +16.1% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-22